Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECiSE 3: Long-term Safety of Certolizumab Pegol in Crohn's Disease
NCT00160524Phase 3Completed
- Sponsor
- UCB
- Start
- Jul 2004
- Primary completion
- Aug 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 29
01
Overview
Phase 3, open-label, single-arm trial of certolizumab pegol in Crohn's disease, sponsored by UCB. Primary endpoints: Percentage of Subjects With at Least One Adverse Event at 84 months and Percentage of Subjects With at Least One Serious Adverse Event at 84 months. Started Jul 2004; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00160524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160524.